Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Austria Belgium Czechia Denmark Finland France +4
  • Study on Durvalumab and Tremelimumab for Patients with Kidney Cancer at Risk of Recurrence After Surgery

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Spain
  • Testing Cabozantinib Dose Skipping Schedule Compared to Dose Reduction in Patients with Kidney Cancer Taking Cabozantinib Treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    The Netherlands
  • A study to evaluate the safety and effectiveness of PTT-4256 and nivolumab in patients with solid tumors.

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    France Spain
  • Study of Pembrolizumab and Enfortumab Vedotin for Patients with Collecting Duct and Renal Medullary Carcinoma

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    Italy
  • Study on the Safety and Effectiveness of AL8326 for Patients with Small Cell Lung Cancer Needing Second-Line Treatment

    Not yet recruiting

    2 1 1
    Investigated Drugs:
    Italy Spain
  • Study on Nivolumab Dose Optimization for Patients with Melanoma or Renal Cell Carcinoma Showing Complete, Partial, or Stable Response

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    The Netherlands
  • Study of Axitinib and Avelumab for Patients with Localized Renal Cell Carcinoma at Moderate to High Risk of Recurrence

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    The Netherlands
  • Study comparing XL092 plus nivolumab versus sunitinib for patients with advanced or metastatic non-clear cell kidney cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Bulgaria Croatia Czechia Denmark Finland France +8
  • Study on Reduced Dose Intensity of Pembrolizumab and Drug Combination for Patients with Advanced or Metastatic Cancer Responding to Standard Immunotherapy

    Not recruiting

    3 1 1 1
    France